Merck & Co. (MRK)
(Delayed Data from NYSE)
$106.34 USD
-2.36 (-2.17%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $106.31 -0.03 (-0.03%) 4:56 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.34 USD
-2.36 (-2.17%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $106.31 -0.03 (-0.03%) 4:56 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
by Zacks Equity Research
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Caterpillar, JPMorgan Chase, Home Depot and Merck & Co
by Zacks Equity Research
Caterpillar, JPMorgan Chase, Home Depot and Merck & Co. are part of the Zacks top Analyst Blog.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.
4 Blue-Chip Stocks to Buy as Dow Seals Record October Gains
by Tirthankar Chakraborty
With the Dow witnessing a sharp run-up in October, investing in stocks like Caterpillar (CAT), JPMorgan (JPM), Home Depot (HD) and Merck (MRK) seems prudent.
Merck (MRK) Upgraded to Buy: Here's Why
by Zacks Equity Research
Merck (MRK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
by Kinjel Shah
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.
Company News for Oct 28, 2022
by Zacks Equity Research
Companies in The News Are: MRK,SHOP,NOC,LUV
Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales.
Merck (MRK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 10.78% and 6.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More
by Zacks Equity Research
Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $93.26, moving -1.43% from the previous trading session.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.